{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:21:48Z","timestamp":1791181308617,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,1,11]],"date-time":"2005-01-11T00:00:00Z","timestamp":1105401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2005,2]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold><jats:italic>Objectives<\/jats:italic>:\u2002To investigate the subjective well\u2010being of patients with newly diagnosed multiple myeloma who were treated in a tandem transplantation programme.<jats:italic>Methods<\/jats:italic>:\u2002Fifty\u2010one patients participated in the prospective, longitudinal questionnaire study. The EORTC QLQ\u2010C30 and the EuroQol\u20105D were administered 2\u2003wk after completion of vincristine, adriamycin and dexamethason\/vincristine, adriamycin and methyl prednison (VAD\/VAMP) chemotherapy, both at hospital discharge after treatment with high\u2010dose melphalan (HDM) and 1\u2003month after this hospital discharge, at hospital admission, at the day of hospital discharge for peripheral stem cell transplantation (PSCT) and at 6 and 12\u2003months following discharge after PSCT.<jats:italic>Results<\/jats:italic>:\u2002Overall, patients\u2019 functioning improved during treatment and follow\u2010up, with significant decreases shortly following PSCT. Shortly after HDM and PSCT, patients reported a considerable increase in levels of soreness in the mouth (+26\/+36 points on a scale ranging form 0 to 100;<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01), change of taste (+23\/+21 points;<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05\/NS), nausea\/vomiting (+26\/+27 points;<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01\/&lt; 0.05), appetite loss (+40\/+43 points;<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001) and diarrhoea (+25\/+36 points;<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01). However, none of these symptoms persisted during follow\u2010up.<jats:italic>Conclusion<\/jats:italic>:\u2002The intensive treatment programme was subjectively being well tolerated by the majority of patients. The duration of declined quality of life after administration of HDM seemed to be short. The duration of subjective recovery after PSCT remained uncertain, but in any case was present at the 6\u2003month follow\u2010up. Together with the rather good results in survival, the evaluation of quality of life invites further exploration of double transplantations in multiple myeloma.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2004.00346.x","type":"journal-article","created":{"date-parts":[[2005,1,11]],"date-time":"2005-01-11T10:26:26Z","timestamp":1105439186000},"page":"136-143","source":"Crossref","is-referenced-by-count":38,"title":["Health related quality of life in patients with multiple myeloma undergoing a double transplantation"],"prefix":"10.1111","volume":"74","author":[{"given":"C. A.","family":"Uyl\u2010de Groot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Buijt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. J. M.","family":"Gloudemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J.","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. P.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. C.","family":"Huijgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,1,11]]},"reference":[{"key":"e_1_2_15_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6935.1033"},{"key":"e_1_2_15_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199402173300709"},{"key":"e_1_2_15_4_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.61.4.285"},{"key":"e_1_2_15_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/107327489800500302"},{"key":"e_1_2_15_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"issue":"51","key":"e_1_2_15_7_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0609.1989.tb01503.x","article-title":"Melphalan\/prednison vs drug combinations for plasma cell myeloma","volume":"43","author":"Bersagel DE.","year":"1989","journal-title":"Eur J Haematol"},{"key":"e_1_2_15_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.334"},{"key":"e_1_2_15_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.5.1298.1298"},{"key":"e_1_2_15_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.759"},{"key":"e_1_2_15_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_15_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.789"},{"key":"e_1_2_15_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032290"},{"key":"e_1_2_15_14_2","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood.V79.11.2827.bloodjournal79112827","article-title":"Double intensive therapy in high risk multiple myeloma","volume":"79","author":"Harousseau JL","year":"1992","journal-title":"Blood"},{"key":"e_1_2_15_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703013"},{"key":"e_1_2_15_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_15_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.352889.x"},{"key":"e_1_2_15_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_15_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199711000-00002"},{"key":"e_1_2_15_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00439229"},{"key":"e_1_2_15_21_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health\u2010related quality of life scores","volume":"16","author":"Osaba D","year":"1998","journal-title":"J Clin Oncol"},{"key":"e_1_2_15_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1999.01279.x"},{"key":"e_1_2_15_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01206.x"},{"key":"e_1_2_15_24_2","doi-asserted-by":"publisher","DOI":"10.1385\/MO:18:1:65"},{"key":"e_1_2_15_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.222667.x"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2004.00346.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2004.00346.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T18:55:34Z","timestamp":1705690534000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2004.00346.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,11]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["10.1111\/j.1600-0609.2004.00346.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2004.00346.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,11]]}}}